Weight Management

Mazdutide

LY3305677 · IBI362

Innovent GLP-1/glucagon dual agonist (IBI362). China Phase 3 GLORY numbers are large. Not FDA-approved as of this catalog date. Not tirzepatide and not retatrutide.

Not FDA-approved - research chemical

Quick answer

What it is: Innovent GLP-1/glucagon dual agonist (IBI362).

Typical research dose: 3-9 mg/week

Reconstitution calculator ↓GLP-1 cost: Medicare, brand-name direct and compounded →GLP-1 with insurance or Medicare ($25 / $50 routes) →Online GLP-1 providers compared →

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Emerging·1 peer-reviewed citation

Typical research dose

3-9 mg/week

Frequency

1× every 2 weeks

Half-life

~6-7 days (once weekly)

Common vials

3 mg / 6 mg / 9 mg

Molecular weight

~4800–5000 Da

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Metabolic / weight7.5/10
China Phase 3 GLORY obesity readouts. Ceiling 8 for Phase 2–3. Haircut: not a US label, and a research vial is not trial material.

Compound card

Sequence: Long-acting GLP-1/glucagon dual agonist (IBI362 / LY3305677)
Class: Once-weekly dual agonist (Innovent; not FDA-approved as of this review)
Formula: Long-acting GLP-1/glucagon dual peptide
Status: Not FDA-approved · research use

Dose it

6 mg + 2 mL BAC water → 3 mg/mL · 3000 mcg ≈ 100 units (U-100)

Open in calculator

How it works

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist (GCGr/GLP-1R) developed by Innovent Biologics. It combines GLP-1 agonism (appetite suppression, insulin secretion) with glucagon receptor agonism (increased hepatic fatty acid oxidation and energy expenditure) - the same glucagon-adding mechanism that makes retatrutide so potent. Phase 3 GLORY trials reported up to 18.6% body weight reduction at 9 mg over 48 weeks in Chinese patients with obesity.

Source: PMID: 37578886

Research Use Cases

✓Obesity / Weight Management: High
✓Metabolic Liver Disease (MASH): Emerging

Dosing

Phase	Dose	Frequency	Notes
Escalation	3 mg → 6 mg → 9 mg	Once weekly (SC)	Phase 3 GLORY protocol: escalate every 4 weeks. 9 mg target dose.

Administration

Route / form

Subcutaneous injection

Timing

Once weekly, same day. Meal timing not required.

Empty stomach?

No - Food timing is not critical.

Timeline

Month 1-3

Rapid weight loss onset - glucagon dual-agonism drives higher early energy expenditure vs GLP-1 alone.

Month 6-12

Up to 18.6% body weight reduction at highest dose in Phase 3 GLORY trials.

Who it is for

Obesity / Weight Management

High

Phase 3: 18.6% BWL at 9 mg over 48 weeks. Approved in China 2024; global regulatory submission pending.

Metabolic Liver Disease (MASH)

Emerging

Glucagon receptor agonism reduces hepatic fat accumulation - early trial signals.

Reconstitution

Vial	Water	Concentration	Example dose
6 mg research/compounded cake	2.0 mL BAC	3 mg/mL	3 mg = 1.0 mL = 100 units on a U-100. This is not GLORY trial supply.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Approved in China (2024) for obesity. Not FDA-approved. GI side effects consistent with GLP-1 class. Investigation ongoing in global Phase 3 trials.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

GLORY describes trial product in a specific population, not a 6 mg cake.
Glucagon agonism is extra energy-expenditure language and extra monitoring (HR, glycogen, lean mass).
Not interchangeable with tirzepatide (GIP/GLP-1) or retatrutide (triple).

Verdict

Mazdutide is a GLP-1 plus glucagon dual agonist in Innovent’s China program. Phase 3 numbers are large. It is not Zepbound and not a US pen on this leaf’s date. Gray-market “mazdutide” is unverified identity.

Interactions & Contraindications

Approved in China (2024) for obesity. Not FDA-approved. GI side effects consistent with GLP-1 class. Investigation ongoing in global Phase 3 trials.

Frequently Asked Questions

Is mazdutide approved in the US?▼

Not yet. Mazdutide was approved in China in 2024 for obesity. Global (including US) Phase 3 trials are ongoing.

How does mazdutide compare to tirzepatide?▼

Both target GLP-1 plus a second receptor. Tirzepatide adds GIP; mazdutide adds glucagon. Mazdutide's glucagon component increases energy expenditure more aggressively. Tirzepatide has more mature global trial data.

References

Ji L et al. “"Mazdutide (IBI362) in Chinese adults with obesity (GLORY-1)".” The Lancet Diabetes & Endocrinology (2024).

📚 Related Articles

Mazdutide: The GLP-1/Glucagon Dual Agonist Efficacy Trial Breakdown

12 min read • GLP-1

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide

14 min read • Pillar Guide

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library